KEAP1 and metabolic dysfunction-associated steatotic liver disease: However, the significant progressive reduction in the expression ratio of Keap-1/Nrf2 after increasing the doses of the phloretamide treatment explains why the livers of these treated rats showed higher nuclear levels of NrfA, similar to the reduction in the activation of Nrf2 in the livers of STZ-diabetic rodents, with or without NAFLD [9,10,11].